Skip to main navigation menu Skip to main content Skip to site footer

Vol. 12 No. 06 (2025)
International Multidisciplinary Journal for Research & Development

Articles

THE NEUROBIOLOGY OF DEPRESSION AND NEW TREATMENT STRATEGIES: UNLOCKING THE MIND’S HIDDEN BATTLES

Published 2025-06-13 — Updated on 2025-06-19

  • Tulayev Bobur Zoyir ugli , Pardayeva Azizabonu Ulug'bek qizi , Asadbek G'aniyev Ulug'bekovich, Eshmuradov Quyoshbek Sanjar ugli, Beknazarov Shahobiddin Fazliddin ugli

Tulayev Bobur Zoyir ugli , Pardayeva Azizabonu Ulug'bek qizi , Asadbek G'aniyev Ulug'bekovich, Eshmuradov Quyoshbek Sanjar ugli, Beknazarov Shahobiddin Fazliddin ugli
Samarkand State Medical University

Abstract

Depression is a leading cause of disability worldwide, affecting more than 280 million people. Traditionally considered a psychological disorder, recent advancements in neuroscience have revealed complex neurobiological underpinnings, including disruptions in neurotransmitter systems, neuroinflammation, and structural brain changes. This article explores the current understanding of the neurobiology of depression and evaluates innovative treatment strategies, such as ketamine, transcranial magnetic stimulation, and psilocybin-based therapy. By bridging classical approaches with novel discoveries, this review aims to shed light on the future direction of depression management.

Keywords

Depression, neurobiology, BDNF, HPA axis, neuroinflammation, ketamine, psilocybin, transcranial magnetic stimulation, treatment-resistant depression, mental health, brain plasticity, monoamine hypothesis, personalized psychiatry

DOWNLOAD PDF

References

  1. World Health Organization. (2023). Depression. https://www.who.int/news-room/fact-sheets/detail/depression
  2. Duman, R.S., & Aghajanian, G.K. (2012). Synaptic dysfunction in depression: potential therapeutic targets. Science, 338(6103), 68–72.
  3. Krystal, J.H. et al. (2019). Ketamine and rapid-acting antidepressants: a new era in psychiatry. Nature Reviews Drug Discovery, 18(3), 145–162.
  4. Carhart-Harris, R.L. et al. (2021). Trial of psilocybin versus escitalopram for depression. NEJM, 384(15), 1402–1411.
  5. Otte, C. et al. (2016). Major depressive disorder. Nature Reviews Disease Primers, 2(1), 1–20.
  6. Malhi, G.S., Mann, J.J. (2018). Depression. The Lancet, 392(10161), 2299–2312.
  7. Felger, J.C., & Miller, A.H. (2012). Cytokine effects on the basal ganglia and dopamine function. Neuropsychopharmacology, 37(1), 137–156.
  8. Caspi, A., et al. (2003). Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science, 301(5631), 386–39.
  9. Gibb, B.E., & Alloy, L.B. (2006). A prospective test of the hopelessness theory of depression. Cognitive Therapy and Research, 30(6), 763–783.

Downloads

Download data is not yet available.